Challenges and Promises

Healing Patients with Heart Failure: the Challenges and Promises of Cell Therapy

July 28th, 2015 (Tuesday)
Venue: Embassy of Belgium

14:00 Door opening
14:20~14:30 Welcome by Ambassador Luc Liebaut
14:30~15:00 Celyad: Origins, development and missions
   Dr. Christian Homsy
   MD, MBA – Chief Executive Officer, Celyad s.a.

15:00~15:45 Perspectives on cardiovascular repair and regeneration in Japan
   Dr. Takayuki Asahara
   MD, PhD - Regenerative Medicine Science, Tokai University School of Medicine

15:45~16:00 Coffee Break

16:00~16:30 Cardiac cell therapy 2.0: the future is now
   Dr. Amit N. Patel
   MD, MS - Director of Clinical Regenerative Medicine, Director of the TAVR Program, Associate Professor of Surgery (Tenured) University of Utah

16:30~17:00 C-Cure® and CHART-1: Clinical effects, multi-center studies
   Dr. Jozef Bartunek
   MD, PhD – Associate Director, Cardiovascular Center, Onze Lieve Vrouw Ziekenhuis, Aalst (Belgium)

17:00~17:30 Delivering products to patients: Innovations in device technology
   Dr. Warren Sherman
   MD - Chief Medical Officer, Celyad s.a.

17:30~17:40 Expanding the opportunities for Celyad therapeutics
   Dr. Georges Rawadi
   PhD, MS - Vice President Business Development, Celyad s.a.

17:40~18:00 Q&A
18:00~20:00 Cocktail reception

Language: English

Organizers: Celyad s.a./Belgium - Wallonia Export-Investment Agency (AWEX)
Honorary Patronage: Embassy of Belgium/Japan Bioindustry Association
Healing patients with heart failure: the challenges and promises of cell therapy

The World Health Organization estimates in 2012 that 31% of deaths worldwide are related to cardiovascular diseases. Left untreated, cardiac diseases can lead to heart failure affecting patients and their families lives in a very distressful way. Despite advances in treatment, heart failure affects one person out of five in the world and experts predict the frequency of this disease to increase as the global population is aging.

Cardio3 BioSciences s.a. was established in 2007 to translate cardio-vascular cell based technologies, originally developed at the Mayo Clinic, from bench to patients in order to effectively treat and potentially even restore the ability of the body to repair itself. Celyad has completed enrollment in a Phase III study in heart failure and is planning for success while patients complete their treatment and the data matures.

A company milestone was reached in May 2015 when Cardio 3 BioSciences became Celyad s.a. The name change now includes its new cell therapy program in immuno-oncology acquired from Dartmouth College USA. Celyad is the global leader in cell therapies with a focus on indications that represent high unmet medical needs. Celyad focuses on cardiovascular disease and cancer, with several products development in pre-clinical and clinical stages.

It is for these reasons that Celyad is proud to invite you to this seminar, share our ambition to treat heart failure, and hear your ideas for taking this innovative technology into clinical study in Japan. During this seminar, Celyad will discuss C-Cure®, its Phase III lead product candidate, an autologous cell therapy using engineered adult stem cells for the treatment of ischemic heart failure. C-Cure® is based on the Mayo Clinic breakthrough Cardiopoiesis platform, exclusively licensed by Celyad.

We would be proud to have you attend this seminar and exchange ideas about shaping the future of patient care for heart failure.

Place: Embassy of Belgium
5-4 Nibancho, Chiyoda-ku,
Tokyo 102-0084
Tel: 03-3556-1061

Organizers: Celyad s.a./Belgium - Wallonia Export-Investment Agency (AWEX)
Honorary Patronage: Embassy of Belgium/Japan Bioindustry Association
Challenges and Promises
Healing patients with heart failure: the challenges and promises of cell therapy

Dr. Christian Homsy  MD, MBA – Chief Executive Officer, Celyad s.a.

Dr. Christian Homsy has been the Chief Executive Officer (CEO) of Celyad since its foundation as Cardio3 Biosciences, in 2007. He obtained his Medical Doctorate at Louvain Catholic University, holds an MBA from the IMD in Lausanne (Switzerland) and gained his business experience in senior research and development, marketing, business development and sales positions at Guidant Corporation, a leading medical device company active in the treatment of cardiovascular disease. He was also founder of Guidant Institute for Therapy Development, a landmark facility for physician and health care professionals’ education that gained international recognition and praise. Before joining Celyad, Dr. Homsy was General Manager of Medpole, a European incubator dedicated to initiating the European operations for start-up companies in the medical device or biotechnology fields. He also holds a director mandate in Medpole s.a.

Dr. Takayuki Asahara  MD, PhD - Regenerative Medicine Science, Tokai University School of Medicine

Dr. Takayuki Asahara is a professor of Regenerative Medicine Science in Tokai University of Medicine. He has primarily discovered endothelial progenitor cells (EPCs) from adult peripheral blood, and published it in Science in 1997, when he was in St. Elizabeth’s Medical Center in Boston, working with Prof. Jeffrey M. Isner. He has investigated and developed a field of EPC biology and therapeutic application for years. The interest is now extended to regenerative medicine researches in terms of vasculogenesis, immunity and inflammation.

Dr. Amit N. Patel  MD, MS - Director of Clinical Regenerative Medicine

Dr. Amit N. Patel, MD, MS, is an associate professor in the Division of Cardiothoracic Surgery at the University of Utah School of Medicine and Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah. His clinical interests include heart surgery for coronary disease, valve repair and replacement, heart failure, aortic surgery and stent grafts. He utilizes minimally invasive surgical approach when possible and this is determined on an individual patient basis. Thoracic interests include lung and esophageal surgery. His interests in thoracic oncology include minimally invasive (VATS) lung resections and hyperthermic chemotherapy for mesothelioma.

Dr. Jozef Bartunek  MD, PhD - Associate Director at Cardiovascular Center, Onze Lieve Vrouw Ziekenhuis, Aalst (Belgium)

After clinical and interventional training, Dr. Jozef Bartunek served as a Fogarty International NIH fellow at Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA. He is a clinician with expertise in interventional cardiology and heart failure. He pursues his research interests in clinical translational research in heart failure and structural heart disease including regenerative and device based interventions. He is a visiting Professor of Medicine at Louvain Catholic University. He published more than 180 per reviewed articles and serves as editor in several cardiovascular journals.

Dr. Warren Sherman  MD - Chief Medical Officer, Celyad s.a.

Dr. Warren Sherman leverages his deep expertise in the cardiovascular and cell therapy fields to support the continued development of Celyad product pipeline, both in cell therapies and cardiovascular diseases. Before joining Celyad as Chief Medical Officer, he was at the Columbia University Medical Center in New York, where he served in a number of capacities, including Interventional Cardiologist at Columbia University Medical Center/New York-Presbyterian Hospital, Director of Stem Cell Research and Regenerative Medicine at the Center for Interventional Vascular Therapy and Associate Professor of Medicine at Columbia University College of Physicians and Surgeons. He is also the founder of the Cardiovascular Research Foundation’s International Conference on Cell Therapy for Cardiovascular Disease (IC3D).

Dr. Sherman received his Bachelors degree from the Massachusetts Institute of Technology, medical degree from the State University of New York Upstate Medical School in Syracuse, and his fellowship training at Oregon Health Sciences University, in Portland, Oregon. He is certified by the American Board of Internal Medicine in Cardiology and Interventional Cardiology, and serves as an advisor to a multitude of government organizations, societies and industries.

Dr. Georges Rawadi  PhD, MS – Vice President Business Development, Celyad s.a.

Dr. Georges Rawadi has served as Vice President Business Development since June 2014. Prior to joining the Company, he was Vice President Business Development at Cellectis. He previously held business development management positions at Galapagos, ProStrakan France and Sanofi-Aventis France, and conducted consultancy assignments in Business Development and Alliance Management. His work included all aspects and stages of business development, driving several projects from target identification and negotiation to closing deals. He holds a PhD in Microbiology from the Pierre et Marie Curie University (France), and a Master in Management and Strategy in the Health Industry from the ESSEC Business School (France).

Organizers: Celyad s.a./Belgium - Wallonia Export-Investment Agency (AWEX)
Honorary Patronage: Embassy of Belgium/Japan Bioindustry Association
返信先 Fax: 03-3262-0398

e-mail: ofijapan@belgium-wallonia.jp

ご返信期日：2015年7月17日

Celyad s.a.
ベルギー王国ワロン地域政府 貿易・外国投資振興庁-AWEX
“Healing patients with heart failure: the challenges and promises of cell therapy”

2015年07月28日（火）14:20〜（14:00 受付開始）
ベルギー王国大使館 102-0084 東京都千代田区二番町5-4

| セミナー | 14:20-18:00 | □ ご出席 □ ご欠席 |
| 懇親会 (カクテル) | 18:00-20:00 | □ ご出席 □ ご欠席 |

□に✔を入れてください

＊英語と日本語の両方でご記入ください

<table>
<thead>
<tr>
<th>御社名</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>ご所属</td>
<td>Dep./Div.</td>
</tr>
<tr>
<td>お役職</td>
<td>Title</td>
</tr>
<tr>
<td>ご芳名</td>
<td>Name</td>
</tr>
<tr>
<td>ご住所</td>
<td>e-mail</td>
</tr>
<tr>
<td>Tel</td>
<td>Fax</td>
</tr>
</tbody>
</table>

＊ご記入頂いた情報は弊事務所にて適切に管理させていただきますが、主催・共催・後援団体からの各種連絡・情報提供のために利用する他、講演者には参加者名簿として配布する場合もございます。

ベルギー王国ワロン地域政府 貿易・外国投資振興庁 — AWEX
〒102-0084 東京都千代田区二番町5-4
Tel: 03-3262-0951 Fax: 03-3262-0398